A Novel GTP-Binding Inhibitor, FX2149, Attenuates LRRK2 Toxicity in Parkinson’s Disease Models
Open Access
- 27 March 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (3) , e0122461
Abstract
Leucine-rich repeat kinase-2 (LRRK2), a cytoplasmic protein containing both GTP binding and kinase activities, has emerged as a highly promising drug target for Parkinson’s disease (PD). The majority of PD-linked mutations in LRRK2 dysregulate its GTP binding and kinase activities, which may contribute to neurodegeneration. While most known LRRK2 inhibitors are developed to target the kinase domain, we have recently identified the first LRRK2 GTP binding inhibitor, 68, which not only inhibits LRRK2 GTP binding and kinase activities with high potency in vitro, but also reduces neurodegeneration. However, the in vivo effects of 68 are low due to its limited brain penetration. To address this problem, we reported herein the design and synthesis of a novel analog of 68, FX2149, aimed at increasing the in vivo efficacy. Pharmacological characterization of FX2149 exhibited inhibition of LRRK2 GTP binding activity by ~90% at a concentration of 10 nM using in vitro assays. Furthermore, FX2149 protected against mutant LRRK2-induced neurodegeneration in SH-SY5Y cells at 50-200 nM concentrations. Importantly, FX2149 at 10 mg/kg (i.p.) showed significant brain inhibition efficacy equivalent to that of 68 at 20 mg/kg (i.p.), determined by mouse brain LRRK2 GTP binding and phosphorylation assays. Furthermore, FX2149 at 10 mg/kg (i.p.) attenuated lipopolysaccharide (LPS)-induced microglia activation and LRRK2 upregulation in a mouse neuroinflammation model comparable to 68 at 20 mg/kg (i.p.). Our results highlight a novel GTP binding inhibitor with better brain efficacy, which represents a new lead compound for further understanding PD pathogenesis and therapeutic studies.Keywords
This publication has 25 references indexed in Scilit:
- Parkinson disease-associated mutation R1441H in LRRK2 prolongs the “active state” of its GTPase domainProceedings of the National Academy of Sciences, 2014
- Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's diseaseTrends in Pharmacological Sciences, 2012
- Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2Nature Chemical Biology, 2011
- Models for LRRK2-Linked ParkinsonismParkinson's Disease, 2011
- LRRK2 as a therapeutic target in Parkinson’s diseaseEuropean Journal of Neurology, 2010
- The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's diseaseNature Reviews Neuroscience, 2010
- Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2—Discovery of LRRK2 inhibitorsAnalytical Biochemistry, 2010
- Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's diseaseNature Medicine, 2010
- Kinetic Mechanistic Studies of Wild-Type Leucine-Rich Repeat Kinase2: Characterization of the Kinase and GTPase ActivitiesBiochemistry, 2010
- Kinase activity of mutant LRRK2 mediates neuronal toxicityNature Neuroscience, 2006